ProstaLund AB (PLUN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.052x

Based on the latest financial reports, ProstaLund AB (PLUN) has a cash flow conversion efficiency ratio of -0.052x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.31 Million ≈ $-248.27K USD) by net assets (Skr44.54 Million ≈ $4.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of ProstaLund AB to measure how much of total assets are equity-financed.

ProstaLund AB - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how ProstaLund AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ProstaLund AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

ProstaLund AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ProstaLund AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Strikewell Energy Corp
V:SKK
0.000x
Premier Miton Group plc
LSE:PMI
0.045x
Kollect on Demand Holding Ab
ST:KOLL
-0.012x
Applied DNA Sciences, Inc.
NASDAQ:BNBX
-0.169x
Sab Events & Governance Now Media Limited
NSE:SABEVENTS
-0.005x
Glen Eagle Resources Inc
V:GER
0.307x
EUROPA MET. LTD POST CONS
F:WRE1
N/A
HSS Hire Group PLC
LSE:HSS
0.141x

Annual Cash Flow Conversion Efficiency for ProstaLund AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of ProstaLund AB from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ProstaLund AB market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr55.18 Million
≈ $5.94 Million
Skr-22.59 Million
≈ $-2.43 Million
-0.409x +4.89%
2023-12-31 Skr55.29 Million
≈ $5.95 Million
Skr-23.80 Million
≈ $-2.56 Million
-0.430x -10.75%
2022-12-31 Skr41.69 Million
≈ $4.49 Million
Skr-16.20 Million
≈ $-1.74 Million
-0.389x -137.43%
2021-12-31 Skr35.46 Million
≈ $3.82 Million
Skr-5.80 Million
≈ $-624.60K
-0.164x +51.64%
2020-12-31 Skr25.35 Million
≈ $2.73 Million
Skr-8.58 Million
≈ $-923.45K
-0.338x +17.44%
2019-12-31 Skr22.23 Million
≈ $2.39 Million
Skr-9.12 Million
≈ $-980.92K
-0.410x +56.18%
2018-12-31 Skr12.71 Million
≈ $1.37 Million
Skr-11.89 Million
≈ $-1.28 Million
-0.936x +20.02%
2017-12-31 Skr13.78 Million
≈ $1.48 Million
Skr-16.11 Million
≈ $-1.73 Million
-1.170x -150.18%
2016-12-31 Skr30.81 Million
≈ $3.32 Million
Skr-14.41 Million
≈ $-1.55 Million
-0.468x -11.23%
2015-12-31 Skr23.19 Million
≈ $2.50 Million
Skr-9.75 Million
≈ $-1.05 Million
-0.420x +53.88%
2014-12-31 Skr11.89 Million
≈ $1.28 Million
Skr-10.83 Million
≈ $-1.17 Million
-0.911x -23.12%
2013-12-31 Skr5.23 Million
≈ $563.26K
Skr-3.88 Million
≈ $-417.01K
-0.740x -33.32%
2012-12-31 Skr4.69 Million
≈ $504.83K
Skr-2.60 Million
≈ $-280.34K
-0.555x --

About ProstaLund AB

ST:PLUN Sweden Medical Care Facilities
Market Cap
$716.78K
Skr6.66 Million SEK
Market Cap Rank
#30745 Global
#723 in Sweden
Share Price
Skr0.21
Change (1 day)
-35.15%
52-Week Range
Skr0.21 - Skr1.95
All Time High
Skr15.54
About

ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more